Researchers have discovered that the novel coronavirus – which causes the respiratory disease COVID-19 – remains stable on surfaces for several hours to days. The new study, undertaken by US National ...

New national surveillance data announced at the UK Health Security Agency (UKHSA) annual conference has demonstrated an increase in antibiotic resistant infections and associated deaths in England.

The US government has announced the ten drugs selected for the first round of pricing negotiations under President Biden’s Inflation Reduction Act (IRA). The IRA allows Medicare, the government health ...

Phase 3 data shows the long-acting antibody combination produces a 77% reduction in the risk of developing symptomatic COVID-19 AstraZeneca has submitted a request to the US Food and Drug ...

Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).

Novo Nordisk and Echosens, a high-technology company specialising in liver diagnostics, have collaborated to advance early diagnosis of non-alcoholic steatohepatitis (NASH). The partnership aims to ...

The US health department has proposed three new models to help lower the cost of drugs, promote accessibility and improve quality of care for those enrolled in voluntary government health insurance ...

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target. The campaign, ...

German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology asset xevinapant. Xevinapant is a potentially first-in-class ...

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk’s Magazine. As technology advances there is a growing array of MedTech solutions – wearables, ...

AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a ...

Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. Under the ...